AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir) and Alcohol / Food Interactions
There are 2 alcohol/food/lifestyle interactions with AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir) which include:
tenofovir ↔ food
Minor Food Interaction
Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
For clinical details see professional interaction data.
High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)
Moderate Potential Hazard, High plausibility
PIs - hyperlipidemia
Hyperlipidemia has been observed in 10% of patients receiving ritonavir during clinical trials. Increases of 30% to 40% from baseline have been reported for total cholesterol and 200% to 300% or more for triglycerides. These effects have also been reported during postmarketing experience with other protease inhibitors (PIs) but may be the most dramatic with ritonavir. The clinical significance of these elevations is unclear. Severe hyperlipidemia is known to sometimes cause pancreatitis. In addition, some patients have reportedly developed symptomatic atherosclerosis and coronary artery disease after initiating PI treatment. Patients with preexisting hyperlipidemia may require closer monitoring during PI therapy, and adjustments made accordingly in their lipid-lowering regimen. PI therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.
- "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.
- "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.
- "Product Information. Invirase (saquinavir)." Roche Laboratories, Nutley, NJ.
- "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.
- Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C "Metabolic effects of indinavir in healthy HIV-seronegative men." Aids 15 (2001): f11-8
- Echevarria KL, Hardin TC, Smith JA "Hyperlipidemia associated with protease inhibitor therapy." Ann Pharmacother 33 (1999): 859-63
- Struble K, Piscitelli SC "Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients." Am J Health Syst Pharm 56 (1999): 2343-8
- "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.
- "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.
- Costa A, Pulido F, Rubio R, Cepeda C, Torralba M, Costa JR "Lipid changes in HIV-infected patients who started rescue therapy with an amprenavir/ritonavir-based highly active antiretroviral therapy." AIDS 16 (2002): 1983-4
- "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.
- Flynn TE, Bricker LA "Myocardial infarction in HIV-infected men receiving protease inhibitors." Ann Intern Med 131 (1999): 548
- "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.
- Segerer S, Bogner JR, Walli R, Loch O, Goebel FD "Hyperlipidemia under treatment with proteinase inhibitors." Infection 27 (1999): 77-81
- "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.
- Sullivan AK, Feher MD, Nelson MR, Gazzard BG "Marked hypertriglyceridaemia associated with ritonavir therapy." AIDS 12 (1998): 1393-4
- "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.
- Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6
- Karmochkine M, Raguin G "Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir." AIDS 12 (1998): 2499
AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir) drug Interactions
There are 726 drug interactions with AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir)
AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir) disease Interactions
There are 11 disease interactions with AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir) which include:
- Renal Dysfunction
- Renal Dysfunction
- Liver Disease
- Bone Toxicity
- Liver Disease
Drug Interaction Classification
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.